Dr. Mihalis Lionakis, MD, ScD is a physician-scientist and Head of the Fungal Pathogenesis Section in NIAID’s Laboratory of Clinical Immunology and Microbiology where he is Deputy Chief. He obtained his MD and ScD from the University of Crete, Greece. He did postdoctoral research training at MD Anderson Cancer Center, followed by Internal Medicine Residency at Baylor College of Medicine, and Infectious Disease Fellowship at NIAID/NIH. He established his own laboratory in 2012 at NIAID and received tenure in 2017. Dr. Lionakis’ laboratory bench-to-bedside research focuses on 1) better understanding the genetic and immune defects that underlie susceptibility to fungal infections in humans and on 2) cellular and molecular factors that regulate the immune response against fungi in clinically relevant animal models. His work has defined precise genetic, biochemical, immunologic, and cellular disease mechanisms that have led to targeted immunotherapies. Dr. Lionakis has published >180 peer-reviewed papers in journals such as Science, Science Translational Medicine, Science Immunology, Nature Immunology, JCI, Journal of Experimental Medicine, Cell Host Microbe, Cancer Cell, and others. He is a Member of the American Society for Clinical Investigation, a Fellow of the American Academy of Microbiology, and a Fellow of the Infectious Diseases Society of America. He has received several awards including the NIH Director’s award, the IDSA Oswald Avery Award for Early Achievement, the Junior Investigator Award from the Immunocompromised Host Society, and the American College of Physicians Walter J. McDonald Award for Early Career Physicians.
- List the key determinants of effective host defense during mucosal versus systemic fungal challenge
- Describe the role of C-type lectin receptor/CARD9 signaling in antifungal immunity
- Describe the immune factors that contribute to mucosal fungal susceptibility in patients with chronic mucocutaneous candidiasis
- Mihalis Lionakis, MD, ScD
This seminar was delivered as a Pediatric Grand Rounds Lecture at Children’s Hospital of Philadelphia, on February 2, 2022.
The work presented in the presentations, videos, and other content on this site (“Presentations”) includes publicly available medical evidence, a consensus of medical practitioners, and/or opinions of individual practitioners that may differ from consensus opinions. These Presentations are intended only to provide general information and need to be adapted for each specific patient based on the practitioner’s professional judgment, consideration of any unique circumstances, the needs of each patient and their family, the availability of various resources at the health care institution where the patient is located, and other factors. The Presentations are not intended to constitute medical advice or treatment, nor should they be relied upon as such. The Presentations are not intended to create a doctor-patient relationship between/among The Children’s Hospital of Philadelphia, its physicians and the individual patients in question. The information contained in these Presentations are general in nature, and do not and are not intended to refer to specific patients.
CHOP, The Children’s Hospital of Philadelphia Foundation and its or their affiliates, the authors, presenters, practitioners, editors, and others associated with the creation of the Presentations (“CHOP”) are not responsible for errors or omissions in the Presentations; for any outcomes a patient might experience where a clinician reviewed one or more such Presentations in connection with providing care for that patient; and/or for any and all third party content on the site or in the Presentations. CHOP makes no warranty, expressed or implied, with respect to the currency, completeness, applicability or accuracy of the Presentations. Application of the information in or to a particular situation remains the professional responsibility of the practitioner who is directly treating the patient.
To the extent that the Presentations include information regarding drug dosing, in view of ongoing research, changes in government regulations and the constant flow of information relating to drug therapy and drug reactions, the viewer should not rely on the Presentation content, but rather is urged to check the package insert for each drug for indications, dosage, warnings and precautions.
Some drugs and medical devices presented in the Presentations have United States Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the practitioner to ascertain the FDA status of each drug or device planned for use in their clinical practice.
You shall indemnify, defend and hold harmless CHOP, The Children’s Hospital of Philadelphia Foundation, and its/their current and former employees, officers, and agents, trustees, and their respective successors, heirs and assigns (“Indemnitees”) against any claims, liability, damage, loss or expenses (including attorneys’ fees and expenses of litigation) in connection with any claims, suits, actions, demands or judgments arising directly or indirectly out of your reference to or use of the Presentations.
The Presentations are protected by copyright laws and in some cases patent laws, and all rights are reserved under such laws. No part of the Presentations may be reproduced in any form by any means, or utilized in any other way, absent prior written permission from the copyright owner.
By starting this module, you agree to our Content Disclaimer and Terms of Service.